 For HCC for which potentially curative therapy is no longer possible, palliative treatment has been proposed by hepatic intra-arterial chemoembolization TACE consisting of an infusion of cisplatin or doxorubicin emulsified with lipiodol, followed by a transient flow blockage achieved by reabsorbable particles gelatin sponge particles. The rationale for the intra-arterial administration of chemotherapy agents in association with embolization material lies in the presence of double hepatic vascularization: hepatocytes are mainly vascularized by the portal structure approximately 90 whereas malignant cells are vascularized by the arterial structure approximately 90. 